-
DE
A tumour vaccine is a cancer immunotherapy that trains the immune system to recognize and attack cancer cells. It represents a promising approach in modern oncology.
A tumour vaccine is a cancer immunotherapy that trains the immune system to recognize and attack cancer cells. It represents a promising approach in modern oncology.
A tumour vaccine (also called a cancer vaccine or antitumour vaccine) is a biological preparation designed to activate or enhance a patient's immune system against cancer cells. Unlike conventional vaccines against infectious diseases, tumour vaccines are primarily used as therapeutic agents to treat existing cancers, although preventive cancer vaccines also exist.
Research into tumour vaccines is one of the most dynamic areas of cancer immunotherapy and has seen remarkable progress in recent years, driven particularly by advances in mRNA technology and personalised neoantigen approaches.
Tumour vaccines exploit tumour-associated antigens – protein structures typically found on the surface of cancer cells – to prime the immune system to recognise and destroy these cells. The process involves several key steps:
These vaccines contain short amino acid sequences (peptides) or full-length proteins that mimic tumour antigens. They are relatively straightforward to manufacture but often require adjuvants (immune-boosting agents) to elicit a sufficiently strong immune response.
In this approach, dendritic cells are harvested from the patient, loaded with tumour antigens in the laboratory, and then re-infused. The best-known example is sipuleucel-T (Provenge), approved for the treatment of castration-resistant prostate cancer.
Using messenger RNA (mRNA) technology, the body's own cellular machinery is instructed to produce tumour antigens. This approach enables rapid and flexible vaccine production and is being actively investigated for personalised cancer vaccines.
Modified viruses are used to deliver genetic information encoding tumour antigens into the body, thereby triggering a targeted immune response against the tumour.
These vaccines consist of killed or attenuated tumour cells derived from the patient or from established cell lines, presenting the immune system with a broad spectrum of tumour antigens simultaneously.
Some tumour vaccines are used for cancer prevention rather than treatment. Notable examples include:
Sipuleucel-T remains one of the few approved therapeutic cancer vaccines worldwide. Numerous additional candidates are currently in Phase I to III clinical trials, including personalised neoantigen vaccines that are tailored to the specific mutations present in an individual patient's tumour.
Particularly promising is the combination of tumour vaccines with immune checkpoint inhibitors (e.g. PD-1/PD-L1 blockade), as this combination can synergistically amplify the anti-tumour immune response. Ongoing trials are evaluating vaccines for melanoma, lung, colorectal, pancreatic, and other cancers.
Tumour vaccines are generally considered well tolerated. Possible side effects include:
Overall, the safety profile of tumour vaccines is considerably more favourable than that of many conventional chemotherapy regimens.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.